{
  "source": "PA-Med-Nec-Crenessity.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2365-2\nProgram Prior Authorization/Medical Necessity\nMedication Crenessity™(crinecerfont) oral capsule and oral suspension\nP&T Approval Date 2/2025, 4/2025\nEffective Date 6/1/2025\n1. Background:\nCrenessity (crinecerfont) is a corticotropin-releasing factor type 1 receptor antagonist indicated\nas adjunctive treatment to glucocorticoid replacement to control androgens in adults and\npediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Crenessity oral capsule or oral suspension will be approved based upon all of the\nfollowing criteria:\na. Diagnosis of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase\ndeficiency\n-AND-\nb. Diagnosis confirmed by one of the following:\n(1) Pretreatment serum 17-hydroxyprogesterone (17-OHP) level > 3,000 ng/dL\n(2) Cosyntropin stimulation 17OHP level > 10,000 ng/dL\n(3) Genetic variant in CYP21A2 gene\n-AND-\nc. Patient is 4 years of age or older\n-AND-\nd. Chronic treatment with a supraphysiologic glucocorticoid (GC) regimen (e.g.,\ndexamethasone, hydrocortisone, methylprednisolone, prednisone, prednisolone)\ndefined as one of the following:\n(1) Both of the following:\n(a) Patient is 4 to 17 years old\n(b) Glucocorticoid dose > 12 mg/m2/day in hydrocortisone dose equivalents\n-OR-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Both of the following:\n(a) Patient is ≥ 18 years old\n(b) Glucocorticoid dose > 13 mg/m2/day in hydrocortisone dose equivalents\n-AND-\ne. Prescribed by an endocrinologist\n-AND-\nf. If the request is for Crenessity oral suspension, one of the following:\n(1) Patient is unable to ingest a solid dosage form (e.g., an oral tablet or capsule) due\nto one of the following:\n(a) age\n(b) oral-motor difficulties\n(c) dysphagia\n-OR-\n(2) Patient utilizes a feeding tube for medication administration\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Cren",
    "llowing:\n(a) age\n(b) oral-motor difficulties\n(c) dysphagia\n-OR-\n(2) Patient utilizes a feeding tube for medication administration\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Crenessity oral capsule or oral suspension will be approved based on all of the\nfollowing criteria:\na. Documentation of positive clinical response to Crenessity therapy (e.g., reduction in\ntotal glucocorticoid daily dose, decreased androstenedione levels)\n-AND-\nb. Patient will continue to receive concomitant glucocorticoid replacement (e.g.,\ndexamethasone, hydrocortisone, methylprednisolone, prednisone, prednisolone)\n-AND-\nc. Prescribed by an endocrinologist\n-AND-\nd. If the request is for Crenessity oral suspension, one of the following:\n(1) Patient is unable to ingest a solid dosage form (e.g., an oral tablet or capsule) due\nto one of the following:\n(a) age\n© 2025 UnitedHealthcare Services, Inc.\n2\n(b) oral-motor difficulties\n(c) dysphagia\n-OR-\n(2) Patient utilizes a feeding tube for medication administration\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Crenessity [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.; December 2024.\n2. Sarafoglou K, Kim MS, Lodish M, et al. Phase 3 Trial of Crinecerfont in Pediatric Congenital\nAdrenal Hyperplasia. N Engl J Med. 2024;391(6):493-503.\n3. Auchus RJ, Hamidi O, Pivonello R, et al. Phase 3 Trial of Crinecerfont in Adult Congenital\nAdrenal Hyperplasia. N Engl ",
    " Pediatric Congenital\nAdrenal Hyperplasia. N Engl J Med. 2024;391(6):493-503.\n3. Auchus RJ, Hamidi O, Pivonello R, et al. Phase 3 Trial of Crinecerfont in Adult Congenital\nAdrenal Hyperplasia. N Engl J Med. 2024;391(6):504-514.\n4. New MI, Lorenzen F, Lerner AJ, et al. Genotyping steroid 21-hydroxylase deficiency:\nhormonal reference data. J Clin Endocrinol Metab. 1983;57(2):320-326.\n5. Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-\nHydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline [published\ncorrection appears in J Clin Endocrinol Metab. 2019 Jan 1;104(1):39-40. J Clin Endocrinol\nMetab. 2018;103(11):4043-4088.\nProgram Prior Authorization/Medical Necessity - Crenessity (crinecerfont)\nChange Control\n2/2025 New program.\n4/2025 Added non-solid dosage form criteria for Crenessity oral suspension.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}